000178291 001__ 178291
000178291 005__ 20241127102004.0
000178291 0247_ $$2doi$$a10.1002/1878-0261.13169
000178291 0247_ $$2pmid$$apmid:34939327
000178291 0247_ $$2ISSN$$a1574-7891
000178291 0247_ $$2ISSN$$a1878-0261
000178291 0247_ $$2altmetric$$aaltmetric:119914263
000178291 037__ $$aDKFZ-2021-03238
000178291 041__ $$aEnglish
000178291 082__ $$a610
000178291 1001_ $$00000-0003-2504-108X$$aKalager, Mette$$b0
000178291 245__ $$aCancer outcomes research - a European challenge Part II: Opportunities and priorities.
000178291 260__ $$aHoboken, NJ$$bJohn Wiley & Sons, Inc.$$c2022
000178291 3367_ $$2DRIVER$$aarticle
000178291 3367_ $$2DataCite$$aOutput Types/Journal article
000178291 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1732699179_12890
000178291 3367_ $$2BibTeX$$aARTICLE
000178291 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000178291 3367_ $$00$$2EndNote$$aJournal Article
000178291 500__ $$a#LA:C110# / 2022 Jun;16(12):2300-2311
000178291 520__ $$aIn Part I of our review of cancer outcomes research, we analysed pros and cons of various measures relevant to quantifying the burden of cancer. Based on our recommendations in Part I, we now discuss in Part II opportunities and priorities in four areas of outcomes research: primary prevention; early detection screening; treatment; and quality of life assessment. We recommend the establishment of an infrastructure that facilitates high quality research in these areas: 1) Progress in primary prevention can be assessed most directly by monitoring cancer incidence although interpretation of temporal trends is notoriously confounded by numerous factors that complicate causal inference. 2) Preventive screening, with the aim to prevent advanced disease, appears to work well in in some tumours but not in others. It will require randomized control trials (RCTs) to quantify benefits and harms although conclusive studies are increasingly difficult to undertake. We therefore propose learning screening programs (randomization at the time of rolling out population-based programs) as the most feasible approach. 3) New therapeutic interventions tailored to the individual patient often require assessment in RCTs with rather complex and dynamic structure, making their design and analyses increasingly challenging but also more suited to be executed as academic, PI-initiated trials. 4) We next discuss assessment of quality of life aspects. Quality of life is a neglected component in outcomes research with an urgent need for development, validation and standardization. We finally recommend four initiatives that would pave the way for a valid and informative assessment of the goals for improved cancer control in Europe as defined by the European Academy of Cancer Sciences.
000178291 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000178291 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000178291 650_7 $$2Other$$a cancer 
000178291 650_7 $$2Other$$aprevention
000178291 650_7 $$2Other$$aquality of life
000178291 650_7 $$2Other$$ascreening
000178291 650_7 $$2Other$$atreatment
000178291 7001_ $$aAdami, Hans-Olov$$b1
000178291 7001_ $$aDickman, Paul W$$b2
000178291 7001_ $$aLagergren, Pernilla$$b3
000178291 7001_ $$0P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aSteindorf, Karen$$b4$$eLast author$$udkfz
000178291 773__ $$0PERI:(DE-600)2322586-5$$a10.1002/1878-0261.13169$$gp. 1878-0261.13169$$n12$$p2300-2311$$tMolecular oncology$$v16$$x1574-7891$$y2022
000178291 909CO $$ooai:inrepo02.dkfz.de:178291$$pVDB
000178291 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000178291 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000178291 9141_ $$y2021
000178291 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-01-28
000178291 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-28
000178291 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-28
000178291 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-28
000178291 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-01-28
000178291 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-01-28
000178291 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-01-28
000178291 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-09
000178291 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-09
000178291 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-09-24T16:36:27Z
000178291 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-09-24T16:36:27Z
000178291 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Open peer review$$d2020-09-24T16:36:27Z
000178291 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-09
000178291 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-09
000178291 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-09
000178291 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOL ONCOL : 2021$$d2022-11-09
000178291 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-09
000178291 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-09
000178291 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bMOL ONCOL : 2021$$d2022-11-09
000178291 9201_ $$0I:(DE-He78)C110-20160331$$kC110$$lBewegung, Präventionsforschung und Krebs$$x0
000178291 980__ $$ajournal
000178291 980__ $$aVDB
000178291 980__ $$aI:(DE-He78)C110-20160331
000178291 980__ $$aUNRESTRICTED